FIGS Management
Management criteria checks 2/4
FIGS' CEO is Trina Spear, appointed in Aug 2022, has a tenure of 3.75 years. total yearly compensation is $8.21M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 4.17% of the company’s shares, worth $80.98M. The average tenure of the management team and the board of directors is 3 years and 4.1 years respectively.
Key information
Trina Spear
Chief executive officer
US$8.2m
Total compensation
| CEO salary percentage | 12.18% |
| CEO tenure | 3.8yrs |
| CEO ownership | 4.2% |
| Management average tenure | 3yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Narrative Update • May 09
FIGS: International Expansion And Margin Recovery Will Drive Future Upside Potential
FIGS' analyst fair value estimate has been raised from $16.31 to $17.75 as analysts point to higher price targets following Q4 results that exceeded expectations, perceived progress on profitable growth, and ongoing opportunities in areas such as international expansion and product initiatives. Analyst Commentary Recent research on FIGS points to a mix of optimism around growth drivers and discipline on profitability, alongside some caution about margins returning to prior levels.
Narrative Update • Apr 21
FIGS: International Expansion And Q4 Execution Are Expected To Sustain Upside Potential
Analysts have lifted the FIGS fair value estimate from $20.00 to $22.00, reflecting higher modeled revenue growth, a richer future P/E multiple, and Street research that points to momentum following recent earnings and international expansion commentary. Analyst Commentary Recent Street commentary around FIGS has turned more constructive, with several bullish analysts adjusting their price targets higher and revisiting their views after the latest quarterly update.Narrative Update • Apr 07
FIGS: International Expansion And Margin Recovery Efforts Will Drive Upside Potential
Narrative Update on FIGS The updated analyst price target for FIGS reflects a modest recalibration in the model inputs. Recent Street research citing Q4 outperformance, improving profitability and customer trends, and longer term opportunities around international expansion and scaling revenue helps explain why analysts continue to refine their $8 to $20 target range for the stock.Narrative Update • Mar 24
FIGS: International Expansion And Margin Recovery Efforts Will Likely Cap Near Term Upside
Narrative Update on FIGS The analyst fair value estimate for FIGS has moved from $9.81 to $16.31 as analysts factor in a series of higher price targets and upgrades that highlight international expansion, margin recovery efforts, and what they describe as sustained recovery and strong momentum following recent Q4 results. Analyst Commentary Recent research on FIGS centers on how the company executes on growth opportunities while working to restore profitability metrics, with price target changes reflecting different views on how quickly that balance can be achieved.Narrative Update • Mar 09
FIGS: Q4 Execution And Specialty Retail Tailwinds Are Expected To Drive Upside
The analyst fair value estimate for FIGS has increased to $20.00 from $15.00, as analysts point to Q4 earnings strength, improved profitability assumptions, and confidence that the company’s platform can support higher long term revenue potential. Analyst Commentary Recent research on FIGS has turned more constructive, with several bullish analysts revising their fair value views higher after the latest Q4 print and updated outlook.Seeking Alpha • Mar 06
FIGS: Hold On To A Uniquely Positioned Company
Summary FIGS Inc., a healthcare apparel company, is beginning to reach an inflection point for its growth on the back of a rejected unsolicited bid for the company. The company is strongly positioned with a fortress balance sheet and operations to deliver long term growth - which will require heavy expenses in the near future. The current valuation of $16.97 proves to be rich when compared to valuations of the company using historical precedents of forward PE. The stock is therefore a "HOLD" for the near term. Read the full article on Seeking AlphaNarrative Update • Feb 23
FIGS: Higher Multiple Assumptions Will Likely Limit Future Share Price Upside
Analysts have nudged their price expectations for FIGS higher, with a modest lift in fair value and future P/E assumptions helping to raise the average price target by about $0.50 as they factor in slightly stronger revenue growth and profit margin potential. Analyst Commentary Recent Street commentary around FIGS points to a mixed but generally constructive stance, with modest price target increases set against ongoing questions about execution and sector risks.
Narrative Update • Feb 09
FIGS: Demand Uncertainty In Specialty Retail Will Constrain Future Share Performance
Analysts have raised their FIGS fair value estimate from about $4.00 to roughly $6.20 per share. This reflects updated assumptions for revenue growth, profit margins, and the future P/E multiple that are in line with recent price target increases from firms such as Morgan Stanley, Barclays, and Roth Capital.Narrative Update • Jan 25
FIGS: Raised Outlook Will Rely On Specialty Retail Tailwinds Into 2026
Narrative Update Analysts have inched up their price targets on FIGS into the high single digit to low double digit US$ range, citing recent research that points to more constructive views on specialty retail through 2026 and firm specific discussions that suggest ongoing business momentum. At the same time, our model keeps fair value steady at US$15.00, with slightly higher revenue growth, margin and future P/E assumptions.Narrative Update • Jan 09
FIGS: Upgraded Outlook Hinges On Strong Brand And Healthcare Apparel Demand
Analysts have lifted their FIGS fair value estimate from US$8.00 to US$15.00, reflecting updated assumptions for revenue growth, profit margins and future P/E, along with a series of recent price target increases from Barclays, Roth Capital, Morgan Stanley, Goldman Sachs and BTIG. Analyst Commentary Recent Street research around FIGS has leaned more constructive, with several bullish analysts lifting price targets and initiating positive coverage.Narrative Update • Dec 26
FIGS: Reduced Discounting Will Likely Cap Upside Despite Recent Business Momentum
Analysts have modestly lowered our FIGS fair value estimate to approximately $9.17 per share from about $9.53, even as they raise price targets into the mid single to low double digits. They cite stronger than expected post Q3 momentum, improving demand trends, and a richer future earnings multiple outlook, despite slightly softer long term growth and margin assumptions.Narrative Update • Dec 12
FIGS: Recent Momentum Will Likely Fade As Reduced Discounting Limits Upside
Our FIGS fair value estimate increases to $9.53 from $8.78 as analysts lift price targets following stronger than expected Q3 results, sustained business momentum signals, and a more constructive view on the brand's long term earnings power. Analyst Commentary Street research on FIGS has turned more constructive overall, with several firms lifting price targets and initiating positive coverage following the company’s strong Q3 performance and improving demand indicators.Narrative Update • Nov 27
FIGS: Share Price Will Likely Reflect Limited Upside Amid Market Caution
Analysts have raised their fair value estimate for FIGS from $7.74 to $8.78, citing stronger than expected business momentum, improved revenue growth expectations, and expanding profit margins. Analyst Commentary Recent research coverage of FIGS has provided a mix of constructive insights and measured caution as analysts adjust their expectations.Narrative Update • Nov 13
FIGS: Future Competitive Pressures Will Likely Limit Further Upside
FIGS’ analyst price target has increased from $6.74 to $7.74 per share. Analysts point to stronger revenue growth expectations and positive trends within the healthcare apparel sector, which support the revised outlook.Analysis Article • Nov 11
There's Reason For Concern Over FIGS, Inc.'s (NYSE:FIGS) Massive 28% Price Jump
The FIGS, Inc. ( NYSE:FIGS ) share price has done very well over the last month, posting an excellent gain of 28%. The...Narrative Update • Oct 30
FIGS: High Market Expectations May Limit Upside As Momentum Slows
Analysts have slightly reduced their price target for FIGS, lowering it from $6.74 to $6.74. The adjustment reflects steady business fundamentals and persistent confidence in the brand's strong positioning within the healthcare apparel market.Narrative Update • Oct 15
Healthcare, E-Commerce And Global Markets Will Fuel Long-Term Success
Analysts have raised their price target for FIGS from $6.42 to $6.74, citing ongoing strength in U.S. healthcare apparel demand and a solid, debt-free balance sheet as supporting factors for the positive adjustment. Analyst Commentary Recent analyst coverage of FIGS has highlighted both encouraging trends and ongoing areas of caution regarding the company's growth trajectory and valuation.Narrative Update • Aug 08
Healthcare, E-Commerce And Global Markets Will Fuel Long-Term Success
The notable upward revision in FIGS' fair value reflects improved consensus revenue growth expectations, more than offsetting the impact of a higher discount rate, resulting in an increased analyst price target from $4.86 to $5.85. What's in the News FIGS, Inc.Analysis Article • Jun 30
There's Reason For Concern Over FIGS, Inc.'s (NYSE:FIGS) Massive 35% Price Jump
FIGS, Inc. ( NYSE:FIGS ) shareholders have had their patience rewarded with a 35% share price jump in the last month...Analysis Article • May 29
It Looks Like FIGS, Inc.'s (NYSE:FIGS) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights FIGS to hold its Annual General Meeting on 4th of June CEO Trina Spear's total compensation includes...Analysis Article • May 09
Subdued Growth No Barrier To FIGS, Inc. (NYSE:FIGS) With Shares Advancing 40%
Those holding FIGS, Inc. ( NYSE:FIGS ) shares would be relieved that the share price has rebounded 40% in the last...Analysis Article • May 03
Is Now The Time To Look At Buying FIGS, Inc. (NYSE:FIGS)?
FIGS, Inc. ( NYSE:FIGS ), might not be a large cap stock, but it led the NYSE gainers with a relatively large price...Seeking Alpha • Apr 24
FIGS, Inc.: Recommending A Hold Despite Tailwinds
Summary FIGS, Inc. is recommended as a “HOLD” due to subpar financial performance and limited upside potential, despite growth plans and strong social media presence. Expansion into untapped markets and new physical stores, particularly in Philadelphia, are key business drivers for FIGS’ future growth. Financial analysis reveals significant declines in EBITDA, net income, and free cash flow, with only a slight increase in net revenue. Tariff risks pose substantial threats to FIGS, potentially increasing production costs and affecting profit margins and demand. Read the full article on Seeking AlphaAnalysis Article • Mar 06
FIGS' (NYSE:FIGS) Soft Earnings Don't Show The Whole Picture
The most recent earnings report from FIGS, Inc. ( NYSE:FIGS ) was disappointing for shareholders. While the headline...Seeking Alpha • Mar 06
Figs, Inc. - Slow Growth Is Still Growth
Summary Figs, Inc. is undervalued, as strong private equity interest and a robust balance sheet indicate potential for significant returns. Favorable growth trends in healthcare employment and broader market appeal support optimistic revenue projections for Figs, Inc. Derived equity value suggests a 25% upside from the current share price, highlighting market undervaluation post-IPO. Superior product quality and brand loyalty, coupled with strategic cash reserves, position Figs, Inc. for steady growth and revenue expansion. Read the full article on Seeking AlphaAnalysis Article • Jan 30
Be Wary Of FIGS (NYSE:FIGS) And Its Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Seeking Alpha • Dec 12
FIGS: Enter A White Knight?
Summary FIGS, Inc. faces stagnating sales and plummeting earnings, with recent Q3/2024 revenues shrinking by 1.5% YoY and operating losses mounting. Private equity firm Story3 Capital Partners is rumored to have offered $6 a share for FIGS, causing a pre-market rally; investors should take advantage and sell their shares. FIGS' valuation may be attractive to Story3, trading at 1.2x Fwd EV/Sales, compared to 2.4x for Nike and 4.6x for Lululemon. Management's diversification efforts have failed; a focus on international DTC medical scrubs could be a winning strategy under new ownership. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
FIGS Back To Q1 Prices, But The Name Is Still A Hold
Summary Figs reported disappointing 3Q24 results with a 2% revenue decline and a 13 percentage point drop in adjusted EBITDA margins, leading to a 30% stock price drop. The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, justifying my Hold rating. Questionable $25 million investment in a pre-product healthcare education app raises concerns about capital allocation and potential conflicts of interest. Despite a great product, Figs' lack of expense control and high valuation make it an unattractive investment at current prices. Read the full article on Seeking AlphaAnalysis Article • Nov 10
The Price Is Right For FIGS, Inc. (NYSE:FIGS) Even After Diving 26%
FIGS, Inc. ( NYSE:FIGS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The...Analysis Article • Oct 18
FIGS (NYSE:FIGS) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysis Article • Oct 03
If EPS Growth Is Important To You, FIGS (NYSE:FIGS) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Oct 03
FIGS, Inc.: Growth Potentially Inflecting Upwards
Summary I rate FIGS, Inc. stock as a buy, expecting growth to inflect upwards with orders per buyer potentially more than doubling. FIGS has enhanced top-of-funnel awareness, product innovation, and distribution capacity, driving customer acquisition beyond its core scrub customer base. Margin pressures are temporary; scaling non-scrub products and the high-margin TEAMS business should flip this headwind into a tailwind. Read the full article on Seeking AlphaAnalysis Article • Sep 18
At US$5.61, Is FIGS, Inc. (NYSE:FIGS) Worth Looking At Closely?
FIGS, Inc. ( NYSE:FIGS ), is not the largest company out there, but it led the NYSE gainers with a relatively large...
New Narrative • Sep 16
Tactical Partnerships And Innovations Propel Brand Expansion And Financial Growth
The partnership with Team USA and innovative product lines like Flare ScrubLegging highlight brand visibility enhancement and market expansion efforts.Seeking Alpha • Sep 05
FIGS Q2 2024 Shows Growth At The Expense Of Margins. The Stock Is Still Overpriced
Summary FIGS' Q2 2024 results showed moderate revenue growth but at the expense of lower margins due to increased spending on products and marketing. The company's lack of cost management and high gross margins make it vulnerable to competition, justifying my Hold rating. Despite some improvement in guidance, the valuation remains unattractive with the stock trading at a high P/E ratio even under optimistic scenarios. I maintain that FIGS is not an opportunity at current prices. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$41m |
| Dec 31 2025 | US$8m | US$1m | US$34m |
| Sep 30 2025 | n/a | n/a | US$18m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$1m |
| Dec 31 2024 | US$5m | US$1m | US$3m |
| Sep 30 2024 | n/a | n/a | US$11m |
| Jun 30 2024 | n/a | n/a | US$19m |
| Mar 31 2024 | n/a | n/a | US$22m |
| Dec 31 2023 | US$8m | US$1m | US$23m |
| Sep 30 2023 | n/a | n/a | US$16m |
| Jun 30 2023 | n/a | n/a | US$14m |
| Mar 31 2023 | n/a | n/a | US$14m |
| Dec 31 2022 | US$1m | US$1m | US$21m |
| Sep 30 2022 | n/a | n/a | US$30m |
| Jun 30 2022 | n/a | n/a | US$33m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$13m | US$852k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$57m |
| Dec 31 2020 | US$40m | US$456k | US$50m |
Compensation vs Market: Trina's total compensation ($USD8.21M) is above average for companies of similar size in the US market ($USD5.47M).
Compensation vs Earnings: Trina's compensation has increased by more than 20% in the past year.
CEO
Trina Spear (41 yo)
3.8yrs
Tenure
US$8,211,946
Compensation
Ms. Catherine Spear, also known as Trina, serves as Venture Partner & LP at Kinship Ventures, LLC. She helps shape the firm’s investment lens around health and performance-driven innovation. She serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 13.3yrs | US$8.08m | 1.94% $ 37.7m | |
| Co-Founder | 3.8yrs | US$8.21m | 4.17% $ 81.0m | |
| Chief Financial Officer | 1.8yrs | US$2.64m | 0.095% $ 1.9m | |
| Chief Technology Officer | 2.7yrs | no data | no data | |
| Senior Vice President of Investor Relations | 2.3yrs | no data | no data | |
| Chief Legal Officer & Secretary | no data | no data | no data | |
| Chief Global Product & Sustainability Officer | 4.2yrs | no data | no data | |
| Chief Business Development Officer | 3.3yrs | no data | no data |
3.0yrs
Average Tenure
42yo
Average Age
Experienced Management: FIGS's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 13.3yrs | US$8.08m | 1.94% $ 37.7m | |
| Co-Founder | 13.3yrs | US$8.21m | 4.17% $ 81.0m | |
| Independent Director | 4.1yrs | US$211.88k | 0.11% $ 2.1m | |
| Lead Independent Director | 4.1yrs | US$202.50k | 0.070% $ 1.4m | |
| Independent Director | 5yrs | US$205.00k | 0.042% $ 823.3k | |
| Independent Director | 1.1yrs | US$234.84k | 0.032% $ 614.7k | |
| Independent Director | 1.3yrs | US$398.70k | 0.0065% $ 125.7k | |
| Independent Director | 7.3yrs | US$217.50k | 1.93% $ 37.4m | |
| Member of Healthcare Advisory Board | 4.1yrs | no data | no data | |
| Member of Healthcare Advisory Board | 4.1yrs | no data | no data | |
| Member of Healthcare Advisory Board | 4.1yrs | no data | no data | |
| Member of Healthcare Advisory Board | 4.1yrs | no data | no data |
4.1yrs
Average Tenure
48yo
Average Age
Experienced Board: FIGS's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 18:15 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FIGS, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adrienne Yih-Tennant | Barclays |
| Robert Drbul | BTIG |
| Brooke Roach | Goldman Sachs |